

Sub
B2
A2

5. (Amended) A method of identifying the location of premalignant or malignant breast cancer within a breast duct or breast ductal network, said method comprising:
providing a premalignant or malignant cancer cell specific identifying agent;
delivering the identifying agent through at least one breast duct in an amount sufficient to identify premalignant or malignant cancerous cells; and
identifying the location of the premalignant or malignant cancerous cells within the at least one breast duct after the coupled compound has been delivered within the at least one duct.

Sub
B3

A3

9. (Amended) A method of determining the lymph node involvement in patients diagnosed with premalignant or malignant breast cancer growths, said method comprising:

providing an identifying agent coupled to a targeting agent;
delivering the coupled compound through at least one breast duct in an amount sufficient to detect lymph node involvement;
determining the lymph node involvement after said coupled compound has been delivered in said at least one breast duct; and
identifying the location of said lymph node involvement.

Sub
B4
A4

13. (Amended) A method of determining the lymph node involvement in patients diagnosed with premalignant or malignant breast cancer growths, said method comprising:

providing an identifying agent;